Creatinine Clearance, Ceftazidime-Avibactam Exposure, and Clinical Outcomes in a Real-World TDM Cohort: A Retrospective Observational Study.
- 1Department of Pharmacy, Tongde Hospital of Zhejiang Province Affiliated to Zhejiang Chinese Medical University, Hangzhou, People's Republic of China.
- 2Department of Critical Care Medicine, Tongde Hospital of Zhejiang Province Affiliated to Zhejiang Chinese Medical University, Hangzhou, People's Republic of China.
- 3Department of Clinical Laboratory Science, Tongde Hospital of Zhejiang Province Affiliated to Zhejiang Chinese Medical University, Hangzhou, People's Republic of China.
Abstract
Purpose
Ceftazidime-avibactam (CAZ-AVI) is a key option for carbapenem-resistant Enterobacterales (CRE) infections, but whether creatinine clearance (CrCL) independently predicts outcomes or reflects disease severity is unclear. We investigated CrCL, drug exposure, and outcomes in patients with severe Gram-negative infections receiving CAZ-AVI with therapeutic drug monitoring (TDM).Patients and methods
This retrospective study included 224 patients receiving CAZ-AVI TDM at a tertiary hospital in China (May 2024-May 2025). Three cohorts were defined: trough-concentration (n=224) for factors influencing trough concentrations; concentration-outcome (n=194) for concentration-outcome associations using LASSO; and stable-dose (n=165) for baseline CrCL and outcomes. CrCL was analysed using restricted cubic splines and five prespecified analysis CrCL strata. Multivariable adjustment, E-values, LASSO, and bootstrap-validated ROC were used to separate CrCL from disease severity.Results
CrCL was the dominant determinant of ceftazidime and avibactam trough concentrations (β = -0.224 and -0.047; q = 0.040 and 0.033, respectively). The unadjusted CrCL-28-day mortality association (OR 0.993, P = 0.030) was attenuated after adjusting for SOFA and APACHE II (OR 0.996, P = 0.285; E-value = 1.07) and after full adjustment (OR 0.996, P = 0.468; E-value = 1.06). LASSO retained SOFA (OR 2.18), CRRT (OR 1.88), age (OR 1.13), and ICU admission (OR 1.03), excluding CrCL. SOFA stratification showed minimal incremental prognostic value for CrCL. The exploratory multivariable model yielded an AUC of 0.760 vs 0.571 for CrCL alone (optimism-corrected AUC: 0.793 vs 0.577).Conclusion
CrCL drives CAZ-AVI trough-concentration variability but appears to be a marker of disease severity rather than an independent predictor of outcomes. Given the observational design and absence of individual MIC data, these findings should be interpreted cautiously. TDM may be best targeted at patients with extreme pharmacokinetic phenotypes, pending prospective validation. Prospective studies with MIC data are needed to define pathogen-specific targets.
Related
- Impact of Adjusted Creatinine Clearance on Carboplatin Dosing in Endometrial Cancer: A Retrospective Study
- Nonlinear association between cockcroft-gault creatinine clearance and all-cause mortality in critically ill cerebrovascular disease patients: a retrospective cohort study
- Outcomes of empirical ceftazidime avibactam plus colistin versus colistin regimens in carbapenem resistant gram negative infection under diagnostic uncertainty
- Association of Carbapenemase Gene Profiles with Ceftazidime–avibactam Resistance in Carbapenem-Resistant Klebsiella pneumoniae
- Investigation on the use of ceftazidime-avibactam at a national hospital in Vietnam
BibTeX
@article{yang2026creatinine,
title = {{Creatinine Clearance, Ceftazidime-Avibactam Exposure, and Clinical Outcomes in a Real-World TDM Cohort: A Retrospective Observational Study.}},
author = {Bo Yang and Jianbiao Meng and Bei Zheng and Juan Wang and Nanmei Chen and Mingwan Zhang and Chuanwei Xin and Meiling Zhang and Yuexing Tu},
journal = {Drug design, development and therapy},
year = {2026},
month = oct,
doi = {10.2147/dddt.s645493},
url = {https://europepmc.org/article/MED/42910240},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Creatinine Clearance, Ceftazidime-Avibactam Exposure, and Clinical Outcomes in a Real-World TDM Cohort: A Retrospective Observational Study.
AU - Bo Yang
AU - Jianbiao Meng
AU - Bei Zheng
AU - Juan Wang
AU - Nanmei Chen
AU - Mingwan Zhang
AU - Chuanwei Xin
AU - Meiling Zhang
AU - Yuexing Tu
PY - 2026
DA - 2026/10/17
JO - Drug design, development and therapy
DO - 10.2147/dddt.s645493
UR - https://europepmc.org/article/MED/42910240
AB - Purpose Ceftazidime-avibactam (CAZ-AVI) is a key option for carbapenem-resistant Enterobacterales (CRE) infections, but whether creatinine clearance (CrCL) independently predicts outcomes or reflects disease severity is unclear. We investigated CrCL, drug exposure, and outcomes in patients with severe Gram-negative infections receiving CAZ-AVI with therapeutic drug monitoring (TDM).Patients and methods This retrospective study included 224 patients receiving CAZ-AVI TDM at a tertiary hospital in China (May 2024-May 2025). Three cohorts were defined: trough-concentration (n=224) for factors influencing trough concentrations; concentration-outcome (n=194) for concentration-outcome associations using LASSO; and stable-dose (n=165) for baseline CrCL and outcomes. CrCL was analysed using restricted cubic splines and five prespecified analysis CrCL strata. Multivariable adjustment, E-values, LASSO, and bootstrap-validated ROC were used to separate CrCL from disease severity.Results CrCL was the dominant determinant of ceftazidime and avibactam trough concentrations (β = -0.224 and -0.047; q = 0.040 and 0.033, respectively). The unadjusted CrCL-28-day mortality association (OR 0.993, P = 0.030) was attenuated after adjusting for SOFA and APACHE II (OR 0.996, P = 0.285; E-value = 1.07) and after full adjustment (OR 0.996, P = 0.468; E-value = 1.06). LASSO retained SOFA (OR 2.18), CRRT (OR 1.88), age (OR 1.13), and ICU admission (OR 1.03), excluding CrCL. SOFA stratification showed minimal incremental prognostic value for CrCL. The exploratory multivariable model yielded an AUC of 0.760 vs 0.571 for CrCL alone (optimism-corrected AUC: 0.793 vs 0.577).Conclusion CrCL drives CAZ-AVI trough-concentration variability but appears to be a marker of disease severity rather than an independent predictor of outcomes. Given the observational design and absence of individual MIC data, these findings should be interpreted cautiously. TDM may be best targeted at patients with extreme pharmacokinetic phenotypes, pending prospective validation. Prospective studies with MIC data are needed to define pathogen-specific targets.
SN - 1177-8881
ER -